Previous 10 | Next 10 |
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, effective Oc...
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi...
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Arbutus Biopharma Corporation (NASDAQ:ABUS), Tata Motors Ltd (NYSE:TTM...
Argenx (NASDAQ: ARGX ) initiated with Outperform rating and $110 (51% upside) price target at Evercore ISI. More news on: Argenx SE, Elanco, KalVista Pharmaceticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
See a week over week comparison below for the following indices, equities, commodities, bonds and currencies. More news on: Youngevity International, Inc., CorMedix Inc., Pyxus International, Inc., Top stock market news, Quick stock ideas, News on the U.S. economy, Financial stocks news, H...
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial Average declined 0.21 percent to close at 26,430.57, while the S&P 500 Index decr...
Arbutus Biopharma ( ABUS -24.1% ) is down on almost triple normal volume in apparent reaction to its announced update on its hepatitis B virus (HBV) programs that includes a delay in the start of a Phase 1 clinical trial evaluating RNA-destabilizer AB-452 in order to allow for more tim...
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve...
WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change to its executive leadership team and provided an update on its key HBV development programs. &...
WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Charda...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...